AVACTA GROUP PLC — Director's Dealing 2017

Jul 28, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4617M

Avacta Group PLC

28 July 2017

28 July 2017

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Director/PDMR Shareholding

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that its Chief Executive Officer, Dr Alastair Smith has today transferred 87,850 ordinary shares of 10p each ("Ordinary Shares") from his personal holding to his self-invested personal pension (SIPP) at a price of 83.0p per Ordinary Share. Following this transaction, Dr Smith's total interest in Ordinary Shares has remained unchanged.

Enquiries:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel:  +44 (0) 844 414 0452 www.avacta.com
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane - Corporate Broking WG Partners David Wilson Nigel Barnes Claes Spang	Tel:  +44 (0) 207 220 0500 www.finncap.com Tel:  +44 (0) 203 705 9318 Tel:  +44 (0) 203 705 9217 www.wgpartners.co.uk
Media Enquiries FTI Consulting Simon Conway / Natalie Garland-Collins	Tel: +44 (0) 203 727 1000 avacta@fticonsulting.com

Notes to Editors

Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.                            

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Alastair Smith

2.                            

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Avacta Group Plc

b)

LEI

n/a

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 10p

Identification code

GB00BYYW9G87

b)

Nature of the transaction

Transfer of ordinary shares to SIPP via a sale and purchase.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
83.0 pence	87,850

d)

Aggregated information:

·      Aggregated volume

·      Price

See above

e)

Date of the transaction

28 July 2017

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHOKFDDBBKDQOB